Abstract | OBJECTIVES: METHODS: CD1 mice were infected with 10(7) cfu of Streptococcus pneumoniae. Treatments (intraperitoneal) with IL-10 (1 microg per mouse), ceftriaxone (20 mg/kg) or the combination of IL-10 + ceftriaxone were initiated 18 h after infection. Groups of mice were sacrificed at several time points from 5 min to 24 h after initiation of therapy. Ceftriaxone was quantified in blood and lungs using a microbiological assay. Additional groups of mice received a second dose of IL-10 at 36 h post- infection. Survival rates were recorded over 14 days. RESULTS: The clearance of ceftriaxone was significantly reduced in infected mice compared with that in non-infected animals (P < 0.01), whereas AUC, mean residence time, t(1/2) and AUC(lung)/AUC(serum) were significantly enhanced (P < 0.01, 0.01, 0.05, 0.05). Co-administration of IL-10 with ceftriaxone in infected animals further retained ceftriaxone in the bloodstream and reduced its volume of distribution at steady state and the ratio of AUC(lung)/AUC(serum). IL-10 alone did not modify significantly the pharmacokinetics of ceftriaxone in blood and lungs of non-infected animals. CONCLUSIONS:
|
Authors | Erjian Wang, Yves Bergeron, Michel G Bergeron |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 55
Issue 5
Pg. 721-6
(May 2005)
ISSN: 0305-7453 [Print] England |
PMID | 15772139
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Interleukin-10
- Ceftriaxone
|
Topics |
- Animals
- Anti-Bacterial Agents
(pharmacokinetics, therapeutic use)
- Ceftriaxone
(pharmacokinetics, therapeutic use)
- Drug Therapy, Combination
- Female
- Inflammation
(drug therapy, immunology, microbiology)
- Interleukin-10
(administration & dosage, therapeutic use)
- Lung
(immunology, microbiology)
- Mice
- Pneumonia, Pneumococcal
(drug therapy, immunology, microbiology, mortality)
- Streptococcus pneumoniae
(drug effects)
|